quite apart from what is being suggested for MPS,
PAR should be knocking on the door of
C S L
for iPPS.
They have shown they are looking for (and found) a growth add-on recently, so an FDA fastpath approval late 2023 could be the the necessary incentive to acquire (part of) another (us).
We can only hope.
IMO. DYOR.
What do they want?, page-28
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.015(4.84%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 29.5¢ | $86.19K | 286.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 70151 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 18600 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |